Advertisement
AZNCF vs NVS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZNCF is a Hold and NVS is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZNCF’s FA Score shows that 1 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).
- AZNCF’s FA Score: 1 green, 4 red.
- NVS’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZNCF’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 4 bullish TA indicator(s).
- AZNCF’s TA Score: 4 bullish, 6 bearish.
- NVS’s TA Score: 4 bullish, 4 bearish.
Price Growth
AZNCF (@Pharmaceuticals: Major) experienced а +0.51% price change this week, while NVS (@Pharmaceuticals: Major) price change was +1.50% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.39%. For the same industry, the average monthly price growth was +1.04%, and the average quarterly price growth was +11.01%.
Reported Earning Dates
NVS is expected to report earnings on Oct 28, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (+1.39% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AZNCF | NVS | AZNCF / NVS | |
| Capitalization | 223B | 198B | 113% |
| EBITDA | 12.9B | 18.3B | 70% |
| Gain YTD | 8.769 | 31.728 | 28% |
| P/E Ratio | 36.10 | 23.38 | 154% |
| Revenue | 44.5B | 46.7B | 95% |
| Total Cash | 5.81B | 14B | 42% |
| Total Debt | 29.8B | 26.3B | 113% |
AZNCF | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 51 | 13 | |
SMR RATING 1..100 | 46 | 29 | |
PRICE GROWTH RATING 1..100 | 58 | 46 | |
P/E GROWTH RATING 1..100 | 82 | 81 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (20) in the Pharmaceuticals Major industry is in the same range as AZNCF (24) in the null industry. This means that NVS’s stock grew similarly to AZNCF’s over the last 12 months.
NVS's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for AZNCF (51) in the null industry. This means that NVS’s stock grew somewhat faster than AZNCF’s over the last 12 months.
NVS's SMR Rating (29) in the Pharmaceuticals Major industry is in the same range as AZNCF (46) in the null industry. This means that NVS’s stock grew similarly to AZNCF’s over the last 12 months.
NVS's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as AZNCF (58) in the null industry. This means that NVS’s stock grew similarly to AZNCF’s over the last 12 months.
NVS's P/E Growth Rating (81) in the Pharmaceuticals Major industry is in the same range as AZNCF (82) in the null industry. This means that NVS’s stock grew similarly to AZNCF’s over the last 12 months.
| AZNCF | NVS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 43% | 2 days ago 53% |
| Stochastic ODDS (%) | 1 day ago 68% | 2 days ago 35% |
| Momentum ODDS (%) | 1 day ago 59% | 2 days ago 49% |
| MACD ODDS (%) | 1 day ago 70% | 2 days ago 56% |
| TrendWeek ODDS (%) | 1 day ago 56% | 2 days ago 43% |
| TrendMonth ODDS (%) | 1 day ago 57% | 2 days ago 45% |
| Advances ODDS (%) | 9 days ago 65% | 9 days ago 49% |
| Declines ODDS (%) | N/A | 21 days ago 45% |
| BollingerBands ODDS (%) | 1 day ago 55% | 2 days ago 43% |
| Aroon ODDS (%) | 1 day ago 56% | 2 days ago 40% |
Advertisement
AZNCF and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZNCF has been loosely correlated with AZN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AZNCF jumps, then AZN could also see price increases.
| Ticker / NAME | Correlation To AZNCF | 1D Price Change % | ||
|---|---|---|---|---|
| AZNCF | 100% | N/A | ||
| AZN - AZNCF | 48% Loosely correlated | +1.40% | ||
| NVS - AZNCF | 24% Poorly correlated | +0.64% | ||
| SNY - AZNCF | 23% Poorly correlated | +1.04% | ||
| MRK - AZNCF | 19% Poorly correlated | +0.37% | ||
| BAYRY - AZNCF | 18% Poorly correlated | +1.00% | ||
More | ||||
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.